One holdover and one SPAC plan to raise $235 million in the holiday week ahead.
Nano-cap auto e-tailer LMP Automotive Holdings (LMPX) plans to raise $12 million at a $45 million market cap. After decreasing its proposed share offering and...read more
Two biotechs and a Chinese real estate company entered the public market, accompanied by two SPACs. All three companies priced at the bottom of the range, while both SPACs upsized their unit offerings. Seven Chinese companies filed for US IPOs, along with two...read more
Oyster Point Pharma, a Phase 3 biotech developing a nasal spray formulation for dry eye disease, raised $80 million by offering 5 million shares at $16, the low end of the range of $16 to $18. Oyster Point Pharma plans to list on the Nasdaq under the symbol...read more
After one of the busiest weeks of the year, just three deals are on the IPO calendar for the week ahead: two biotechs and a Chinese real estate platform, which...read more
US IPO Week Ahead: The IPO market takes its Thanksgiving break
One holdover and one SPAC plan to raise $235 million in the holiday week ahead. Nano-cap auto e-tailer LMP Automotive Holdings (LMPX) plans to raise $12 million at a $45 million market cap. After decreasing its proposed share offering and...read more
US IPO Weekly Recap: More deals price down in a 3-IPO week
Two biotechs and a Chinese real estate company entered the public market, accompanied by two SPACs. All three companies priced at the bottom of the range, while both SPACs upsized their unit offerings. Seven Chinese companies filed for US IPOs, along with two...read more
Eye disease biotech Oyster Point Pharma prices IPO at $16 low end
Oyster Point Pharma, a Phase 3 biotech developing a nasal spray formulation for dry eye disease, raised $80 million by offering 5 million shares at $16, the low end of the range of $16 to $18. Oyster Point Pharma plans to list on the Nasdaq under the symbol...read more
US IPO Week Ahead: IPO market is ghosted with just 3 deals this week
After one of the busiest weeks of the year, just three deals are on the IPO calendar for the week ahead: two biotechs and a Chinese real estate platform, which...read more